Vaginal estrogen: why it is treated differently from HRT

What it treats

Genitourinary syndrome of menopause covers the changes to vulva, vagina, urethra and bladder as estrogen falls: dryness, burning, itching, pain during sex, urinary urgency and frequency, discomfort passing urine, and recurrent urinary tract infections.

It differs from other menopause symptoms in that it progresses rather than resolving. Hot flashes eventually stop; this does not, which is why the strategy of waiting is wrong here specifically.

Why the risk conversation is different

Systemic hormone therapy raises circulating hormone levels throughout the body, which is what the discussion of breast cancer, clot and stroke risk relates to.

Low-dose vaginal preparations deliver estrogen to the tissue itself. Systemic absorption is minimal and blood levels generally remain within the postmenopausal range.

Because of that, guidance treats it as a distinct intervention: it does not require a progestogen for endometrial protection at standard low doses in women with a uterus, it is not considered to carry the systemic risks attributed to systemic therapy, and long-term use is generally regarded as appropriate.

Product leaflets frequently carry warnings copied from systemic hormone therapy, which alarms people and is a recognised source of unnecessary discontinuation. It is worth asking about rather than acting on alone.

After breast cancer

This is the situation where the question arises most sharply, and the honest answer is that it is a specialist discussion rather than a simple yes or no.

Guidance generally supports considering local vaginal estrogen for women with a history of breast cancer whose genitourinary symptoms have not responded to non-hormonal measures, after discussion with their oncology team. The consideration is more cautious for women taking aromatase inhibitors than tamoxifen.

Non-hormonal options are usually tried first in this group, and there are also non-estrogen prescription treatments. Anyone in this position should have the conversation rather than assume the door is closed, because assuming is common and often wrong.

Practical points people are not told

• It takes weeks, not days. Several weeks of consistent use before judging it is normal
• Benefit continues only while treatment continues, because the underlying tissue change resumes when it stops
• Most regimens start with a more frequent loading phase then reduce to a maintenance frequency
• Preparations differ in form — pessary, cream, ring, gel — and preference matters for whether it is actually used
• Moisturisers and lubricants work alongside it rather than instead: lubricant addresses friction, estrogen addresses the tissue

When to see someone

Raise it directly, because you are unlikely to be asked. Clinicians frequently do not enquire about vaginal and urinary symptoms and patients frequently do not volunteer them, which is why a highly effective treatment goes unused for years.

Mention recurrent urinary tract infections in the same conversation. Local vaginal estrogen has trial evidence for reducing recurrence, and that indication is often missed entirely.

Get any bleeding after twelve months without a period assessed rather than attributed to the treatment.